{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:55:37Z","timestamp":1787698537700,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.leukres.2024.107518","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T01:08:12Z","timestamp":1715389692000},"page":"107518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS\/MPN"],"prefix":"10.1016","volume":"142","author":[{"given":"Guillermo","family":"Montalban-Bravo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kanagal-Shammana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2024.107518_bib1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2024.107518_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107518_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2024.107518_bib4","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1080\/10428194.2018.1436705","article-title":"Hypomethylating agents (HMAs) effect on myelodysplastic\/myeloproliferative neoplasm unclassifiable (MDS\/MPN-U): single institution experience","volume":"59","author":"Al-Kali","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"13","key":"10.1016\/j.leukres.2024.107518_bib5","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood-2017-06-788497","article-title":"Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS\/MPN","volume":"130","author":"Jabbour","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2024.107518_bib6","doi-asserted-by":"crossref","first-page":"E246","DOI":"10.1002\/ajh.26182","article-title":"Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome\/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS\/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)","volume":"96","author":"Montalban-Bravo","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.leukres.2024.107518_bib7","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1002\/cncr.33622","article-title":"Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia","volume":"127","author":"Montalban-Bravo","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2024.107518_bib8","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2024.107518_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"Hollenbach","year":"2010","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.leukres.2024.107518_bib10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2024.107518_bib11","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.leukres.2024.107518_bib12","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107518_bib13","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ejh.12469","article-title":"Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome","volume":"94","author":"Lee","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2024.107518_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107518_bib15","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.leukres.2015.10.005","article-title":"Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk. Res"},{"issue":"12","key":"10.1016\/j.leukres.2024.107518_bib16","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMc1108665","article-title":"Point mutations in myelodysplastic syndromes","volume":"365","author":"Masuda","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107518_bib17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-12-304","article-title":"Myeloid malignancies: mutations, models and management","volume":"12","author":"Murati","year":"2012","journal-title":"BMC Cancer"},{"issue":"7257","key":"10.1016\/j.leukres.2024.107518_bib18","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature08240","article-title":"Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms","volume":"460","author":"Sanada","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.leukres.2024.107518_bib19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2007-01-066076","article-title":"Flt3-dependent transformation by inactivating c-Cbl mutations in AML","volume":"110","author":"Sargin","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2024.107518_bib20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.exphem.2012.10.016","article-title":"Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases","volume":"41","author":"Polzer","year":"2013","journal-title":"Exp. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107518_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2010.09.008","article-title":"Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling","volume":"18","author":"Rathinam","year":"2010","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.leukres.2024.107518_bib22","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1182\/blood-2012-06-436675","article-title":"Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling","volume":"120","author":"Taylor","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107518_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16092","article-title":"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies","author":"Weisberg","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2024.107518_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2024.107518_bib25","article-title":"Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3mut+) relapsed\/refractory (R\/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial","author":"Perl","year":"2019","journal-title":"AACR Annu. Meet."},{"issue":"10388","key":"10.1016\/j.leukres.2024.107518_bib26","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.leukres.2024.107518_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107518_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000353118","article-title":"Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition","volume":"141","author":"Simons","year":"2013","journal-title":"Cytogenet Genome Res"},{"issue":"9","key":"10.1016\/j.leukres.2024.107518_bib29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107518_bib30","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107518_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"issue":"10","key":"10.1016\/j.leukres.2024.107518_bib32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2024.107518_bib33","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2024.107518_bib34","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2024.107518_bib35","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1038\/leu.2013.165","article-title":"Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML","volume":"27","author":"Takahashi","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2024.107518_bib36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107518_bib37","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2022-170069","article-title":"RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia","volume":"140","author":"Montalban-Bravo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2024.107518_bib38","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1078-0432.CCR-08-1325","article-title":"CBL exon 8\/9 mutants activate the FLT3 pathway and cluster in core binding factor\/11q deletion acute myeloid leukemia\/myelodysplastic syndrome subtypes","volume":"15","author":"Reindl","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2024.107518_bib39","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1182\/blood.V130.Suppl_1.723.723","article-title":"The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I\/II Trial","volume":"130","author":"Swaminathan","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2024.107518_bib40","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107518_bib41","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2017.85","article-title":"A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials","volume":"31","author":"Montalban-Bravo","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2024.107518_bib42","doi-asserted-by":"crossref","first-page":"997 e1","DOI":"10.1016\/j.jtct.2021.09.005","article-title":"Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.leukres.2024.107518_bib43","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/10428194.2012.737917","article-title":"A phase I\/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186","volume":"54","author":"Macdonald","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2024.107518_bib44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/10428190903585286","article-title":"A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study","volume":"51","author":"Crump","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"25","key":"10.1016\/j.leukres.2024.107518_bib45","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2024.107518_bib46","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0301-472X(02)00903-7","article-title":"Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo","volume":"30","author":"Ramshaw","year":"2002","journal-title":"Exp. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T19:43:39Z","timestamp":1720208619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":46,"alternative-id":["S0145212624000845"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107518","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS\/MPN","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107518"}}